Literature DB >> 32115315

You say "schizophrenia" and I say "psychosis": Just tell me when I can come off this medication.

Robert B Zipursky1, Gbolahan Odejayi2, Ofer Agid3, Gary Remington4.   

Abstract

Individuals experiencing a first episode of psychosis are likely to respond well to treatment with antipsychotic medications. Of those treated for a first episode of schizophrenia, three out of four can expect to achieve remission. The question of how long antipsychotic medication should be continued has been a topic of heated debate in the field. Longitudinal studies of individuals diagnosed with a first episode of psychosis have reported that as many as 30% may be able to come off of medications without relapsing while treatment discontinuation studies have found that very few patients remain in remission off of medication. This paper reviews the literature on relapse rates following a first episode of schizophrenia and identifies factors that contribute to the discrepancies in the rates reported. These factors include sampling considerations, the distribution of psychiatric diagnoses, the duration of follow-up, the rate of medication discontinuation and the criteria used to define illness recurrence. We propose that individuals for whom the diagnosis of their first psychotic episode is determined with ongoing follow-up to be due to schizophrenia are at extremely high risk of relapse and should be advised to continue antipsychotic medication for the long-term. Those whose first episode of psychosis is determined to be due to other causes are also at high risk of illness recurrence off medications. Recommendations for maintenance treatment should be tailored to reflect the risk of relapse and sequelae of relapse associated with specific causes of first episode psychosis.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antipsychotic medication; First episode psychosis; Maintenance treatment; Outcome; Relapse; Schizophrenia

Mesh:

Substances:

Year:  2020        PMID: 32115315     DOI: 10.1016/j.schres.2020.02.009

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  1 in total

1.  An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders.

Authors:  Nadia E Crellin; Stefan Priebe; Nicola Morant; Glyn Lewis; Nick Freemantle; Sonia Johnson; Rob Horne; Vanessa Pinfold; Lyn Kent; Ruth Smith; Katherine Darton; Ruth E Cooper; Maria Long; Jemima Thompson; Lisa Gruenwald; Robert Freudenthal; Jacki L Stansfeld; Joanna Moncrieff
Journal:  BMC Psychiatry       Date:  2022-03-15       Impact factor: 3.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.